← Advanced Bronchoscopy

Comparing Monarch Versus Ion Robotic-Assisted Bronchoscopy Platforms

IPBronch Review

🎯 Background & Rationale

While robotic-assisted bronchoscopy (RAB) has revolutionized the sampling of peripheral pulmonary lesions, previous literature has been limited to single-arm studies evaluating platforms (primarily the Monarch and Ion systems) in isolation. Due to varying diagnostic yield definitions and disparate patient cohorts, direct comparisons between platforms have been lacking. This study addresses the clinical gap by providing the first direct comparative analysis between the Monarch and Ion robotic bronchoscopy platforms.

👥 Study Design & Population

  • Study Type: Single-center retrospective observational cohort study with propensity score-matched analysis.
  • Population: 365 adult patients who underwent RAB biopsy of a single target pulmonary lesion (Monarch N = 162, Ion N = 203) between November 2021 and December 2023 in a sequential, non-overlapping timeframe.

📈 Methodology & Rigor

To minimize selection bias between the nonrandomized, sequentially introduced groups, the authors performed 1:1 propensity score matching utilizing a genetic search algorithm (GenMatch in R) matching for age, sex, nodule size, location, and presence of a bronchus sign. Diagnostic yield (DY) was defined strictly using criteria endorsed by the American Thoracic Society and ACCP. Primary outcomes (DY and pneumothorax) were evaluated using conditional logistic regression, while quantitative outcomes (procedure and radiation metrics) utilized mixed models treating matches as random factors.

🔬 Key Findings [or Planned Endpoints]

  • Diagnostic Yield: The Ion platform demonstrated a significantly higher unadjusted diagnostic yield compared to Monarch (84.2% [171/203] vs. 71.0% [115/162], P = 0.003), supported by propensity score matching (adjusted OR: 2.29, 95% CI: 1.42–3.70).
  • Procedural Efficiency: Ion cases had significantly shorter robot procedure times (median 37.0 vs. 70.0 min, P < 0.001), radiation duration (4.6 vs. 8.0 min, P < 0.001), and lower radiation dose area product (DAP: 22.7 vs. 40.0 Gy·cm², P < 0.001).
  • Complications: Pneumothorax rates were 1.0% (Ion) versus 4.3% (Monarch), showing a lower adjusted risk for pneumothorax with Ion (adjusted OR: 0.13, 95% CI: 0.03–0.62).
  • Confounders: A 1.1 mm cryoprobe was utilized in 193/203 Ion cases versus only 10/162 Monarch cases. Cone-beam CT (CBCT) integration with the Cios system was utilized more frequently with Monarch (95.1%) than Ion (80.3%).

⚖️ Critical Appraisal

Internal validity is strengthened by the rigorous propensity score matching and the application of a strict, standardized diagnostic yield definition. However, significant methodological limitations temper the conclusions:

  1. Confounding Variables: The study is heavily confounded by the near-exclusive use of the 1.1 mm cryoprobe in the Ion cohort versus the Monarch cohort, which may independently drive differences in diagnostic yield.
  2. Sequential Bias: Platforms were evaluated in non-overlapping historical time blocks (Monarch first, Ion second), raising the possibility of proceduralist learning curve bias.
  3. CBCT Integration: Differences in CBCT utilization and system integration features (such as Cios integration with Ion) introduce unmeasured technical variance.

💡 The Clinical Bottom Line

While this retrospective comparison suggests that the Ion platform yields higher diagnostic accuracy with shorter procedure times and lower radiation exposure compared to Monarch, definitive superiority cannot be claimed due to substantial confounding variables—specifically the asymmetric adoption of the 1.1 mm cryoprobe and procedural learning curves. Clinicians must await data from properly randomized controlled trials (such as FROSTBITE-II) before altering platform preference based on retrospective data alone.


Background: Lung cancer is the leading cause of cancer-related deaths. Earlier detection and diagnosis are crucial in improving overall survival. Limitations in conventional bronchoscopic biopsy techniques have prompted the development of robotic-assisted bronchoscopy (RAB) platforms. Among the RAB platforms, we report the first study comparing outcomes between the Ion and Monarch platforms. Methods: In this single-center retrospective study, data were collected from adults (age>18 y) who underwent a RAB biopsy with the Monarch (11/23/21 to 3/10/23) or by the Ion (3/21/23 to 12/15/23). The primary outcome was diagnostic yield (DY). The secondary outcomes were robot procedure duration, radiation time, radiation dose, and complication rate. We performed propensity score-matched analysis. Results: A total of 365 patients (Monarch N=162, Ion N=203) were included in the analysis. DY for Ion and Monarch was 84.2% versus 71.0%, respectively (P=0.003). When compared with Monarch, Ion cases had a shorter robot procedure time [median (IQR): 37.00 (26.00, 51.00) vs. 70.00 (51.25, 87.00) min, P<0.001], shorter radiation time [median (IQR) 4.6 (3.00, 7.10) vs. 8.0 (5.80, 10.95) minutes, P<0.001], and lower radiation dose area product (DAP) [median (IQR): 22.70 (14.30, 38.35) vs. 40.00 (23.20, 67.80) Gy.cm2, P<0.001]. Pneumothorax rates were 1.0% versus 4.3% for Ion and Monarch, respectively (P=0.089). Conclusion: This is a retrospective study that suggests that the Ion RAB system, when compared with the Monarch RAB system, had higher DY, shorter robot procedure time and radiation time, and lower radiation dose. A randomized controlled trial is needed to confirm or refute these findings.
Read the full paper ↗

Keep reading

N opens the next one